Notably, two distinct genetic scores based on single nucleotide polymorphisms (SNPs) in the angiotensin II receptor type 1 gene (AGTR1) and bradykinin receptor B1 gene (BDKRB1), as well as the ACE gene (ACE) and ABO blood group genes (ABO), respectively, were recently found to predict ACEI efficacy and ACE activity in European patients with stable ischemic heart disease (IHD) and in Asian patients with young-onset hypertension, respectively [9–12]. This evidence concerns the gene ABO and myocardial ischemia.